BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 30268464)

  • 1. Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?
    Merino Lara T; Helou J; Poon I; Sahgal A; Chung HT; Chu W; Soliman H; Ung Y; Verma S; Cheema P; Cheng S; Khanna S; Erler D; Zhang L; Cheung P
    Lung Cancer; 2018 Oct; 124():219-226. PubMed ID: 30268464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter.
    Thompson R; Cheung P; Chu W; Myrehaug S; Poon I; Sahgal A; Soliman H; Tseng CL; Wong S; Ung Y; Beatriz Kinupe Abrahão A; Erler D; Zhang L; Ko YJ; Chung HT
    Radiother Oncol; 2020 Jan; 142():236-245. PubMed ID: 31543287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: Treatment indication matters.
    Tan H; Cheung P; Louie AV; Myrehaug S; Niglas M; Atenafu EG; Chu W; Chung HT; Poon I; Sahgal A; Soliman H
    Radiother Oncol; 2021 Aug; 161():159-165. PubMed ID: 34119585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors.
    Ji X; Zhao Y; Zhu X; Shen Z; Li A; Chen C; Chu X
    Front Oncol; 2020; 10():595781. PubMed ID: 33585211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
    Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
    Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
    Shahi J; Poon I; Ung YC; Tsao M; Bjarnason GA; Malik NH; Zhang L; Louie AV; Cheung P
    Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):764-774. PubMed ID: 33115687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT.
    Hörner-Rieber J; Bernhardt D; Blanck O; Duma M; Eich HT; Gerum S; Gkika E; Hass P; Henkenberens C; Herold HU; Hildebrandt G; Imhoff D; Kahl H; Janssen S; Jurianz K; Krempien R; Lautenschläger SF; Lohaus F; Mueller AC; Petersen C; Sackerer I; Scafa D; Schrade E; Uhlmann L; Wittig A; Guckenberger M
    Clin Lung Cancer; 2019 Nov; 20(6):e667-e677. PubMed ID: 31327644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
    Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
    Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity and Efficacy of Multitarget Thoracic Stereotactic Body Radiation Therapy.
    Nguyen EK; Poon I; Ung YC; Tsao M; Korol R; Elzibak AH; Erler D; Zhang L; Louie AV; Cheung P
    Int J Radiat Oncol Biol Phys; 2023 Mar; 115(4):897-905. PubMed ID: 36368432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy.
    Sharma A; Duijm M; Oomen-de Hoop E; Aerts JG; Verhoef C; Hoogeman M; Nuyttens JJ
    Acta Oncol; 2019 Jan; 58(1):74-80. PubMed ID: 30280633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
    Kann BH; Miccio JA; Stahl JM; Ross R; Verma V; Dosoretz AP; Park HS; Shafman TD; Gross CP; Yu JB; Decker RH
    Radiother Oncol; 2019 Mar; 132():188-196. PubMed ID: 30391106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
    Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
    BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
    Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
    BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter.
    Helou J; Thibault I; Poon I; Chiang A; Jain S; Soliman H; Erler D; Yeung L; Cheung P
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):419-427. PubMed ID: 28463162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy for synchronous early stage non-small cell lung cancer.
    Steber CR; Hughes RT; Soike MH; Helis CA; Nieto K; Jacobson T; Nagatsuka M; McGinnis HS; Leyrer CM; Farris MK
    Acta Oncol; 2021 May; 60(5):605-612. PubMed ID: 33645424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiotherapy for distant metastases to the head and neck.
    Mutsaers A; Abugharib A; Poon I; Loblaw J; Bayley A; Zhang L; Chin L; Galapin M; Erler D; Sahgal A; Higgins K; Enepekides D; Eskander A; Karam I
    Support Care Cancer; 2024 Mar; 32(4):230. PubMed ID: 38488881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study.
    Miyakawa A; Shibamoto Y; Baba F; Manabe Y; Murai T; Sugie C; Yanagi T; Takaoka T
    Radiat Oncol; 2017 Sep; 12(1):152. PubMed ID: 28893300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study.
    Mazzola R; Fersino S; Ferrera G; Targher G; Figlia V; Triggiani L; Pasinetti N; Lo Casto A; Ruggieri R; Magrini SM; Alongi F
    Med Oncol; 2018 Aug; 35(9):121. PubMed ID: 30076479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer.
    Ager BJ; Wells SM; Gruhl JD; Stoddard GJ; Tao R; Kokeny KE; Hitchcock YJ
    Lung Cancer; 2019 Dec; 138():6-12. PubMed ID: 31593894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.